Literature DB >> 8040120

Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa.

B Fantin1, R Farinotti, A Thabaut, C Carbon.   

Abstract

The conditions for the emergence of resistance to cefpirome and ceftazidime were studied in rabbits with experimental aortic endocarditis due to Pseudomonas aeruginosa. The MIC of cefpirome was 16 mg/L and that of ceftazidime was 4 mg/L. Resistant mutants with MICs of > or = 64 mg/L were obtained in vitro to cefpirome after a single passage and to ceftazidime after five passages. A single dose of 50 mg/kg intramuscularly gave mean peak serum concentrations of 110.0 +/- 31.7 mg/L for cefpirome compared with 67.7 +/- 21.4 mg/L for ceftazidime and the half-lives were 1.2 +/- 0.1 h and 2.1 +/- 0.4 h, respectively. After treating infected rabbits for 4 days with various dosing regimens, resistant strains were only detected in those animals in which the time that the serum concentration exceeded the MIC was less than half of the dosing interval. There was no evidence of emergent resistance when the serum concentrations exceeded the MIC for a longer period nor when amikican was combined with the cephalosporins on the first day of therapy. Moreover, once differences in MICs and pharmacokinetics were taken into account, both antibiotics had a similar propensity to induce resistance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8040120     DOI: 10.1093/jac/33.3.563

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

Review 1.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

2.  [S2 Guideline for diagnosis and therapy of infectious endocarditis].

Authors:  C K Naber
Journal:  Z Kardiol       Date:  2004-12

3.  Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections.

Authors:  Peter Ankomah; Bruce R Levin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

4.  Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing.

Authors:  J Lipman; S C Wallis; C Rickard
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 5.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Therapeutic Drug Monitoring of Continuous Infusion Doripenem in a Pediatric Patient on Continuous Renal Replacement Therapy.

Authors:  Jeffrey J Cies; Wayne S Moore; Susan B Conley; Paul Shea; Adela Enache; Arun Chopra
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jan-Feb

7.  Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group.

Authors:  J Lipman; J Scribante; A G Gous; H Hon; S Tshukutsoane
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

8.  Pharmacokinetics of Continuous Infusion Meropenem With Concurrent Extracorporeal Life Support and Continuous Renal Replacement Therapy: A Case Report.

Authors:  Jeffrey J Cies; Wayne S Moore; Susan B Conley; Mindy J Dickerman; Christine Small; Dominick Carella; Paul Shea; Jason Parker; Arun Chopra
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb

9.  Altered pharmacokinetics of ceftazidime in critically ill patients.

Authors:  C M Gómez; J J Cordingly; M G Palazzo
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

10.  Stability of Amoxicillin and Clavulanic Acid in Separate Containers for Administration via a Y-Site.

Authors:  Sarah Fawaz; Mahboub Merzouk; Stephen Barton; Shereen Nabhani-Gebara
Journal:  Drug Des Devel Ther       Date:  2021-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.